Evidence map›Paper›PMID 39173508›Full record

ArticleNeoplasia (New York, N.Y.)2024

Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics.

Zeqi Niu, Molly Kozminsky, Kathleen C Day, Luke J Broses, Marian L Henderson, Christopher Patsalis, Rebecca Tagett, Zhaoping Qin, Sarah Blumberg, Zachery R Reichert and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zeqi NiuDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerface Institute, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Molly KozminskyDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerface Institute, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Kathleen C DayDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Luke J BrosesDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Marian L HendersonDepartment of Internal Medicine, Hematology Oncology Division, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Christopher PatsalisDepartment of Internal Medicine, Hematology Oncology Division, University of Michigan, Ann Arbor, MI 48109, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Rebecca TagettBioinformatics Core, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Zhaoping QinDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Sarah BlumbergDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Zachery R ReichertDepartment of Internal Medicine, Hematology Oncology Division, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Sofia D MerajverDepartment of Internal Medicine, Hematology Oncology Division, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Aaron M UdagerDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Phillip L PalmbosDepartment of Internal Medicine, Hematology Oncology Division, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Sunitha NagrathDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerface Institute, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: snagrath@umich.edu.
Mark L DayDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: mday@umich.edu.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Environmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6M
Label free microfluidic isolation, characterization and ex vivo expansion of CTCsR01CA208335 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NAGRATH, SUNITHA · 2017 to 2021
$2.8M
Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder CancerR37CA273138 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PHILLIP L PALMBOS · 2022 to 2026
$2.2M
High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug TestingR33CA202867 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NAGRATH, SUNITHA, RAMNATH, NITHYA · 2016 to 2018
$1.0M
NCI NIH HHS P30 CA046592NCI NIH HHS R01CA208335NCI NIH HHS R33 CA202867NCI NIH HHS R37 CA273138NCI NIH HHS U01 CA210152
6 · The paper itself

Abstract

Assessing the molecular profiles of bladder cancer (BC) from patients with locally advanced or metastatic disease provides valuable insights, such as identification of invasive markers, to guide personalized treatment. Currently, most molecular profiling of BC is based on highly invasive biopsy or transurethral tumor resection. Liquid biopsy takes advantage of less-invasive procedures to longitudinally profile disease. Circulating tumor cells (CTCs) isolated from blood are one of the key analytes of liquid biopsy. In this study, we developed a protein and mRNA co-analysis workflow for BC CTCs utilizing the graphene oxide (GO) microfluidic chip. The GO chip was conjugated with antibodies against both EpCAM and EGFR to isolate CTCs from 1 mL of blood drawn from BC patients. Following CTC capture, protein and mRNA were analyzed using immunofluorescent staining and ion-torrent-based whole transcriptome sequencing, respectively. Elevated CTC counts were significantly associated with patient disease status at the time of blood draw. We found a count greater than 2.5 CTCs per mL was associated with shorter overall survival. The invasive markers EGFR, HER2, CD31, and ADAM15 were detected in CTC subpopulations. Whole transcriptome sequencing showed distinct RNA expression profiles from patients with or without tumor burden at the time of blood draw. In patients with advanced metastatic disease, we found significant upregulation of metastasis-related and chemotherapy-resistant genes. This methodology demonstrates the capability of GO chip-based assays to identify tumor-related RNA signatures, highlighting the prognostic potential of CTCs in metastatic BC patients.

Indexed as

Biomarkers, TumorMicrofluidicsNeoplastic Cells, CirculatingUrinary Bladder NeoplasmsAgedCell Line, TumorErbB ReceptorsFemaleHumansLiquid BiopsyMaleMiddle AgedNeoplasm MetastasisPrognosisBiomarkers, TumorErbB ReceptorsADAM15Bladder cancerCD31Circulating tumor cellsDifferential gene expressionEGFRGraphene oxide microfluidic chipHER2Targeted transcriptome sequencing

Identifiers

PMID39173508
PMCPMC11387905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.